Cannabidiol effects on Anxiety and Insomnia
DOI:
https://doi.org/10.60988/p.v38i1.293Keywords:
CBD, Anxiety, Cannabidiol, Sleep.Abstract
One of the active cannabinoids in cannabis is cannabidiol (CBD), which does not cause euphoria or alter consciousness like tetrahydrocannabinol (THC) does. According to new research, CBD may be useful in treating several neuropsychiatric disorders, such as schizophrenia, anxiety, and epilepsy. Additionally, research indicates that CBD has a relaxing impact on the central nervous system. Clinical evidence in psychiatric research is still scarce, despite increased interest in its medicinal applications. According to a psychiatric clinic's retrospective analysis, CBD was used in conjunction with traditional therapies to assist in treating anxiety and sleep-related problems. In this chart analysis, 103 adult patients' monthly anxiety and sleep quality measurements were recorded. Of the sample as a whole, 72 people stated that their main problems were anxiety (47%) or sleep issues (25%). 57 participants (79.2%) showed a decrease in anxiety symptoms during the first month of treatment, and this improvement continued during the observation period. Although there were some variations over time, 48 individuals (66.7%) saw an improvement in their sleep quality over the first month. Only three people reported negative effects, indicating that CBD was generally well tolerated. Although carefully planned controlled clinical trials are required to establish its efficacy and safety, these data imply that cannabidiol may offer therapeutic advantages for anxiety.
References
1. Wade A. The societal costs of insomnia. Neuropsychiatr Dis Treat. 2010;6:3–7.
2. Fernandez-Mendoza J, Vgontzas AN. Insomnia and its impact on physical and mental health. Curr Psychiatry Rep. 2013;15(12):418.
3. Khan MS, Aouad R. The effects of insomnia and sleep loss on cardiovascular disease. Sleep Med Clin. 2022;17(2):193–203.
4. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: a systematic review. Cannabis Cannabinoid Res. 2022. doi:10.1089/can.2022.0089.
5. Elmasry A, Lindberg E, Berne C, Janson C, Gislason T, Tageldin MA, et al. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med. 2001;249(2):153–61.
6. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep. 1999;22 Suppl 2:S379–85.
7. Punnoose AR, Golub RM, Burke AE. Insomnia. JAMA. 2012;307(24):2653–4.
8. Roth T, Krystal AD, Lieberman JA. Long-term issues in the treatment of sleep disorders. CNS Spectr. 2007;12(7 Suppl 10):1–14.
9. Pusparani A. A review on insomnia: the sleep disorder. Scientia Psychiatrica. 2021;3(2):172–6.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: APA Publishing; 2013.
11. American Sleep Disorders Association. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. Revised ed. Rochester, MN: ASDA; 2001.
12. Spielman AJ, Nunes J, Glovinsky PB. Insomnia. Neurol Clin. 1996;14(3):513–43.
13. Perlis M, Shaw PJ, Cano G, Espie CA. Models of insomnia. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. 5th ed. Philadelphia: Elsevier; 2011. p. 850–65.
14. Sateia MJ. International classification of sleep disorders–third edition: highlights and modifications. Chest. 2014;146(5):1387–94.
15. Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med Rev. 1997;1(2):97–108.
16. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15.
17. Harvey AG. A cognitive model of insomnia. Behav Res Ther. 2002;40(8):869–93.
18. Clinton JM, Davis CJ, Zielinski MR, Jewett KA, Krueger JM. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med. 2011;7(5 Suppl):S38–42.
19. Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, et al. Cortical GABA levels in primary insomnia. Sleep. 2012;35(6):807–14.
20. Lack LC, Mercer JD, Wright H. Circadian rhythms of early morning awakening insomniacs. J Sleep Res. 1996;5(4):211–9.
21. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–63.
22. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010;68(6):1023–42.
23. Martinez Naya N, Kelly J, Corna G, Golino M, Polizio AH, Abbate A, et al. An overview of cannabidiol as a multifunctional drug: pharmacokinetics and cellular effects. Molecules. 2024;29(2):473.
24. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180–8.
25. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477–82.
26. Bardhi K, Coates S, Watson CJW, Lazarus P. Cannabinoids and drug metabolizing enzymes: potential for drug–drug interactions and implications for drug safety and efficacy. Expert Rev Clin Pharmacol. 2022;15(12):1443–60.
27. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.
28. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003;93(3):377–87.
29. Messina G, Rovelli F, Lissoni P, Lissoni PA. Review of psychobiological differences among tetrahydrocannabinol, cannabinol, cannabidiol and cannabigerol. Clin Rev Cases. 2022;4(2):1–4.
30. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333–49.
31. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139–54.
32. Grotenhermen F, Müller-Vahl K. Cannabis und Cannabinoide in der Medizin: Fakten und Ausblick. Suchttherapie. 2016;17(2):71–6.
33. Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: a critical review on clinical trials. Exp Clin Psychopharmacol. 2019;27(4):383–401.
34. Pearce DD, Mitsouras K, Irizarry KJ. Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. J Altern Complement Med. 2014;20(10):787–91.
35. Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. Patient-reported symptom relief following medical cannabis consumption. Front Pharmacol. 2018;9:916.
36. Vigil JM, Stith SS, Diviant JP, Brockelman F, Keeling K, Hall B. Effectiveness of raw, natural medical cannabis flower for treating insomnia under naturalistic conditions. Medicines (Basel). 2018;5(3):75.
37. Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697.
38. Soleymanpour M, Saderholm S, Kavuluru R. Therapeutic claims in cannabidiol (CBD) marketing messages on Twitter. In: 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). Piscataway, NJ: IEEE; 2021. p. 3083–8.
39. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S–27S.
40. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea: identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013;188(8):996–1004.
41. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708–9.
42. Oberbarnscheidt T, Miller NS. The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res. 2020;12(7):393–403.
43. Hilderbrand RL. Hemp and cannabidiol: what is a medicine? Mo Med. 2018;115(4):306–9.
44. Drug Enforcement Administration. Establishment of a new drug code for marihuana extract. Fed Regist. 2016;81(240):90194–6.
45. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783–6.
46. Anciones C, Gil-Nagel A. Adverse effects of cannabinoids. Epileptic Disord. 2020;22(S1):S13–6.
47. Machado Bergamaschi M, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237–49.
48. Biehl JR, Burnham EL. Cannabis smoking in 2015. Chest. 2015;148(3):596–606.
49. Tan WC, Sin DD. What are the long-term effects of smoked marijuana on lung health? CMAJ. 2018;190(42):E1243–4.
50. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19.
